MONALEESA-3 更新总生存:瑞波西利联合氟维司群治疗 HR+/HER2- 晚期乳腺癌
MONALEESA-3 是一项 III 期随机双盲安慰剂对照试验,入组 726 例 HR+/HER2- 晚期乳腺癌患者,按 2:1 随机接受瑞波西利或安慰剂联合氟维司群。更新随访中位 56.3 个月时,瑞波西利组中位 OS 为 53.7 个月,安慰剂组为 41.5 个月(HR 0.73,95%CI 0.59-0.90),未观察到新的安全性信号。
要点
- 瑞波西利联合氟维司群较单药氟维司群延长中位 OS 约 12 个月。
- 一线亚组中位 OS 安慰剂组 51.8 个月,HR 0.64(95%CI 0.46-0.88)。
- 二线亚组中位 OS 瑞波西利组 39.7 个月 vs 33.7 个月,HR 0.78(95%CI 0.59-1.04)。
核心结论
- 在 HR+/HER2- 晚期乳腺癌患者中,瑞波西利联合氟维司群较氟维司群单药延长中位 OS 约 12 个月。
- 更新随访未观察到瑞波西利与氟维司群之间明显的药物相互作用或新的安全性信号。
研究设计与样本
- III 期随机双盲安慰剂对照试验,在 30 个国家 174 个中心开展。
- 入组 726 例组织学/细胞学确诊的 HR+/HER2- 晚期乳腺癌患者,按 2:1 随机分配至瑞波西利组(484 例)或安慰剂组(242 例)。
- 患者允许接受 ≤1 线内分泌治疗但未接受过晚期乳腺癌化疗,按肝/肺转移 presence/absence 和既往内分泌治疗分层。
- 治疗方案为肌注氟维司群 500 mg(每 28 天周期第 1 天,第 1 周期第 15 天加用)联合口服瑞波西利 600 mg/天(服 3 周停 1 周)或安慰剂。
- OS 为次要终点,疗效分析基于意向治疗人群,安全性分析纳入至少接受 1 剂研究治疗的患者。
主要发现
- 数据截止 2020 年 10 月 30 日,中位随访 56.3 个月时,瑞波西利组中位 OS 为 53.7 个月,安慰剂组为 41.5 个月(HR 0.73,95%CI 0.59-0.90)。
- 亚组分析结果与总体人群一致。
- 一线治疗亚组中,瑞波西利组约 60% 患者生存超过中位随访时间,安慰剂组中位 OS 为 51.8 个月(HR 0.64,95%CI 0.46-0.88)。
- 二线治疗亚组中,瑞波西利组中位 OS 为 39.7 个月,安慰剂组为 33.7 个月(HR 0.78,95%CI 0.59-1.04)。
临床怎么用
- 对于 HR+/HER2- 晚期乳腺癌绝经后女性和男性患者,瑞波西利联合氟维司群可作为内分泌治疗联合方案选择。
- 一线亚组显示更显著的 OS 获益(HR 0.64),支持该联合方案在早期治疗线中的应用。
- 二线亚组 OS 获益趋势一致但置信区间跨越 1,临床决策需结合患者具体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ribociclib plus fulvestrant demonstrated significant progression-free survival (PFS) and overall survival (OS) benefits in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). Here we present a new landmark in survival follow-up for a phase III cyclin-dependent kinases 4 and 6 inhibitor clinical trial in patients with ABC (median, 56.3 months). PATIENTS AND METHODS: This phase III, randomized, double-blind, placebo-controlled trial was conducted at 174 sites (30 countries). Patients were men and postmenopausal women (age ≥18 years) with histologically/cytologically confirmed HR+/HER2- ABC. Patients could have received ≤1 line of endocrine therapy (ET) but no chemotherapy for ABC. Patients, assigned 2:1, were stratified by the presence/absence of liver/lung metastases and previous ET. Patients received intramuscular fulvestrant (500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1) with oral ribociclib (600 mg/day, 3 weeks on, 1 week off) or placebo. Efficacy analyses were by intention to treat. Safety was assessed in patients receiving ≥1 dose study treatment. OS was a secondary endpoint. MONALEESA-3 is registered with ClinicalTrials.gov (NCT02422615; no longer enrolling). RESULTS: Between 18 June 2015 and 10 June 2016, 726 patients were randomly assigned (484, ribociclib; 242, placebo). At data cut-off (30 October 2020), median OS (mOS) was 53.7 months (ribociclib) versus 41.5 months (placebo) [hazard ratio (HR), 0.73; 95% confidence interval (CI) 0.59-0.90]. Subgroup analyses were consistent with overall population. In the first-line setting, most patients in the ribociclib arm (∼60%) lived longer than median follow-up; mOS was 51.8 months in the placebo arm (HR, 0.64; 95% CI 0.46-0.88). In the second-line setting, mOS was 39.7 months (ribociclib) versus 33.7 months (placebo) (HR, 0.78; 95% CI 0.59-1.04). No apparent drug-drug interaction between ribociclib and fulvestrant or new safety signals were observed. CONCLUSIONS: This analysis reported extended OS follow-up in MONALEESA-3. mOS was ∼12 months longer in patients with HR+/HER2- ABC treated with ribociclib plus fulvestrant compared with fulvestrant monotherapy.
引用
- Slamon DJ, Neven P, Chia S, et al. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival. Ann Oncol. 2021. PMID: 34102253. doi:10.1016/j.annonc.2021.05.353
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。